Fundamental Analysis of ATARA BIOTHERAPEUTICS INC(NASDAQ:ATRA) stock

Fundamental Rating

ATRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ATRA may be in some trouble as it scores bad on both profitability and health. ATRA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ATRA has reported negative net income.

In the past year ATRA has reported a negative cash flow from operations.

In the past 5 years ATRA always reported negative net income.

In the past 5 years ATRA always reported negative operating cash flow.

1.2 Ratios

ATRA's Return On Assets of -166.84% is on the low side compared to the rest of the industry. ATRA is outperformed by 87.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-166.84%
ROE	N/A
ROIC	N/A

ROA(3y)-100.05%

ROA(5y)-87.43%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ATRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ATRA does not have a ROIC to compare to the WACC, probably because it is not profitable.

ATRA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ATRA has more shares outstanding

ATRA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -22.08, we must say that ATRA is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -22.08, ATRA is not doing good in the industry: 86.99% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-22.08

ROIC/WACCN/A

WACC7.83%

2.3 Liquidity

A Current Ratio of 0.72 indicates that ATRA may have some problems paying its short term obligations.

With a Current ratio value of 0.72, ATRA is not doing good in the industry: 93.66% of the companies in the same industry are doing better.

A Quick Ratio of 0.65 indicates that ATRA may have some problems paying its short term obligations.

ATRA's Quick ratio of 0.65 is on the low side compared to the rest of the industry. ATRA is outperformed by 93.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.72
Quick Ratio	0.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.68% over the past year.

Looking at the last year, ATRA shows a very negative growth in Revenue. The Revenue has decreased by -86.50% in the last year.

EPS 1Y (TTM)3.68%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q22.22%

Revenue 1Y (TTM)-86.5%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q1832.73%

3.2 Future

The Earnings Per Share is expected to grow by 13.02% on average over the next years. This is quite good.

The Revenue is expected to grow by 57.61% on average over the next years. This is a very strong growth

EPS Next Y72.96%

EPS Next 2Y33.68%

EPS Next 3Y20.86%

EPS Next 5Y13.02%

Revenue Next Year551.33%

Revenue Next 2Y132.04%

Revenue Next 3Y64.37%

Revenue Next 5Y57.61%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ATRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ATRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ATRA's earnings are expected to grow with 20.86% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.68%

EPS Next 3Y20.86%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ATRA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (4/26/2024, 3:07:47 PM)

After market: 0.7099 +0.02 (+2.88%)

0.69

-0.01 (-1.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap82.36M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-166.84%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.72
Quick Ratio	0.65
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)3.68%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y72.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-86.5%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ATARA BIOTHERAPEUTICS INC (ATRA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens